source
- FDA approves Regeneron's siRNA drug Livsayis for myasthenia gravis, expanding its neurology portfolioRegeneron has received FDA clearance for its siRNA‑based therapy cemdisiran, now marketed as Livsayis, to treat myasthenia gravis. This approval is the second new myasthenia gravis drug cleared by…
- U.S. loses measles elimination status as outbreaks claim first deaths in decadesThe Pan American Health Organization announced that the United States has lost its measles elimination status, a designation it held for 26 years. The decision follows a year‑long period of sustain…